Cytek Biosciences (CTKB) Tax Provisions (2020 - 2026)

Cytek Biosciences has reported Tax Provisions for 7 years, with the latest figure at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions rose 1400.0% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $38.1 million (up 1096.92% YoY), and the FY2025 full-year result was $36.7 million, up 11368.12% from the prior year.
• Tax Provisions for Q1 2026 stood at $1.5 million, down from $40.0 million in the prior quarter.
• The five-year high for Tax Provisions was $40.0 million in Q4 2025, with the low at -$2.8 million in Q1 2024.
• Historically, Tax Provisions has averaged $2.0 million across 5 years, with a median of -$699000.0 in 2022.
• Annual changes were most pronounced in 2022 — Tax Provisions plunged 2390.0% — and 2025, when it surged 5788.97%.
• Cytek Biosciences' Tax Provisions stood at $396000.0 in 2022, then sank by 443.69% to -$1.4 million in 2023, then soared by 149.96% to $680000.0 in 2024, then surged by 5788.97% to $40.0 million in 2025, then slumped by 96.25% to $1.5 million in 2026.
• The last three Tax Provisions figures came in at $1.5 million (Q1 2026), $40.0 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.